Last reviewed · How we verify
the ginsenoside Rg3
At a glance
| Generic name | the ginsenoside Rg3 |
|---|---|
| Also known as | Shen Yi capsule |
| Sponsor | ShenFeng |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma (NA)
- Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study (PHASE4)
- the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- the ginsenoside Rg3 CI brief — competitive landscape report
- the ginsenoside Rg3 updates RSS · CI watch RSS
- ShenFeng portfolio CI